Gra­cell gives sneak peek in­to leukemia CAR-T cell pro­gram ahead of EHA

Gra­cell Biotech­nolo­gies said Thurs­day af­ter­noon that its CAR-T treat­ment for pa­tients with B cell acute lym­phoblas­tic leukemia, or B-ALL, helped clear signs of can­cer in sev­en of nine pa­tients at a me­di­an fol­low-up of over one year.

In a Phase I tri­al in Chi­na of Gra­cell’s CAR-T treat­ment, dubbed GC007g, with pa­tients with re­lapsed B-ALL, all pa­tients went in­to re­mis­sion one month af­ter treat­ment. At a me­di­an fol­low-up of 445 days (with a wide range of fol­low-up from 218 to 649 days), sev­en of nine pa­tients re­mained in re­mis­sion, while two had a CD19-neg­a­tive re­lapse.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.